A necessary first step in the evaluation of SYK inhibitors in clinical trials involving patients with AML would thus involve the measurement of P-SYK in routine clinical samples, preferably using a method amenable to widespread adoption. The gene discussed is SYK; the disease is acute myeloid leukemia.